Analytical Data
-
基因名
KCNQ5
- Application
-
别名
KCNQ 5; KCNQ5; KCNQ5_HUMAN; KQT like 5 ; KQT-like 5; Kv7.5; OTTHUMP00000064152; OTTHUMP00000064153; Potassium channel alpha subunit KvLQT5; Potassium channel protein; Potassium channel subunit alpha KvLQT5; Potassium voltage gated channel KQT like subfamily member 5; Potassium voltage gated channel subfamily KQT member 5
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NR82
-
表达区间
1-932aa
-
氨基酸序列
MPRHHAGGEEGGAAGLWVKSGAAAAAAGGGRLGSGMKDVESGRGRVLLNSAAARGDGLLLLGTRAATLGGGGGGLRESRRGKQGARMSLLGKPLSYTSSQSCRRNVKYRRVQNYLYNVLERPRGWAFIYHAFVFLLVFGCLILSVFSTIPEHTKLASSCLLILEFVMIVVFGLEFIIRIWSAGCCCRYRGWQGRLRFARKPFCVIDTIVLIASIAVVSAKTQGNIFATSALRSLRFLQILRMVRMDRRGGTWKLLGSVVYAHSKELITAWYIGFLVLIFSSFLVYLVEKDANKEFSTYADALWWGTITLTTIGYGDKTPLTWLGRLLSAGFALLGISFFALPAGILGSGFALKVQEQHRQKHFEKRRNPAANLIQCVWRSYAADEKSVSIATWKPHLKALHTCSPTKKEQGEASSSQKLSFKERVRMASPRGQSIKSRQASVGDRRSPSTDITAEGSPTKVQKSWSFNDRTRFRPSLRLKSSQPKPVIDADTALGTDDVYDEKGCQCDVSVEDLTPPLKTVIRAIRIMKFHVAKRKFKETLRPYDVKDVIEQYSAGHLDMLCRIKSLQTRVDQILGKGQITSDKKSREKITAEHETTDDLSMLGRVVKVEKQVQSIESKLDCLLDIYQQVLRKGSASALALASFQIPPFECEQTSDYQSPVDSKDLSGSAQNSGCLSRSTSANISRGLQFILTPNEFSAQTFYALSPTMHSQATQVPISQSDGSAVAATNTIANQINTAPKPAAPTTLQIPPPLPAIKHLPRPETLHPNPAGLQESISDVTTCLVASKENVQVAQSNLTKDRSMRKSFDMGGETLLSVCPMVPKDLGKSLSVQNLIRSTEELNIQLSGSESSGSRGSQDFYPKWRESKLFITDEEVGPEETETDTFDAAPQPAREAAFASDSLRTGRSRSSQSICKAGESTDALSLPHVKLK
-
分子量
102 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KCNQ5, a member of the KCNQ gene family, encodes voltage-gated potassium channels that play a critical role in setting the resting membrane potential and regulating neuronal excitability. The study of KCNQ5 has garnered significant attention due to its involvement in various physiological processes and its implications in neurological disorders. Mutations in the KCNQ5 gene have been linked to benign familial neonatal seizures (BFNS) and other forms of epilepsy, highlighting its importance in neuronal function. Research on KCNQ5 recombinant proteins has primarily focused on understanding their biophysical properties, pharmacological profiles, and functional mechanisms. These studies typically involve heterologous expression systems to analyze channel behavior, including activation, inactivation, and ion selectivity. Additionally, KCNQ5 channels are influenced by various modulators, including small molecules and lipids, making them potential therapeutic targets for epilepsy treatment. Recent advancements in structural biology methods, such as cryo-electron microscopy, have enhanced our understanding of the channel's architecture and dynamics. By investigating KCNQ5 recombinant proteins, researchers aim to elucidate the underlying mechanisms of ion channel dysfunctions and develop novel strategies for therapeutic interventions in channelopathies associated with KCNQ5. This research represents a critical step towards harnessing the therapeutic potential of KCNQ5 modulation in managing neurological diseases.
